<DOC>
	<DOCNO>NCT00399750</DOCNO>
	<brief_summary>A randomize , control , open-label multicenter trial ass safety efficacy 3 oxaliplatin-fluoropyrimidine containing regimen ( mFOLFOX6 ; bFOL ; XELOX ) + Bevacizumab ( TREE1 TREE2 ) first line therapy advance metastatic colorectal cancer .</brief_summary>
	<brief_title>TREE-2 : Three Regimens Eloxatin Advanced Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>The following information clinical trial provide information purpose allow patient physician initial discussion trial . This information intend complete information trial , contain consideration may relevant potential participation trial , replace advice personal physician health professional . INCLUSION CRITERIA : Subjects must meet follow inclusion criterion eligible enrollment study : 1 . Histologically documented adenocarcinoma colon , rectum appendix . 2 . Metastatic/recurrent disease amenable potentially curative treatment ( e.g. , inoperable metastatic disease ) . 3 . No prior chemotherapy metastatic/recurrent disease . Prior adjuvant treatment 5FU/LV and/or IFL allow complete least 6 month study registration . 4 . ECOG Performance Status 0 1 . 5 . At least one unidimensionally measurable lesion diameter &gt; /= 20 mm use conventional CT MRI scan &gt; /= 10 mm use spiral CT scan . If single lesion identify target lesion , histological cytological confirmation adenocarcinoma require . 6 . Recovery full previous surgical procedure . 7 . No serious concomitant disease . 8 . Required baseline laboratory parameter : 1 . Absolute neutrophil count ( ANC ) &gt; /=1,500/mm3 ( standard international [ SI ] unit 109/L ) ; 2 . Platelets &gt; /= 100,000/mm3 ( SI unit 109/L ) ; 3 . Hemoglobin &gt; /= 8.0 g/dL ( SI unit mmol/L ) ; 4 . Creatinine &lt; /= 1.5 x ULN ; Total bilirubin &lt; /= 2.0 x ULN ; 5 . Serum glutamateoxalate transferase ( SGOT , AST ) Serum glutamic pyruvic transaminase ( SGPT , ALT ) &lt; /= 3 x ULN &lt; /= 3 x ULN ; 6 . Urinalysis dipstick Protein &lt; +1 ; 7 . Coagulation PT/PTT ( INR ) Within Normal Limits Institution ; 8 . Serum pregnancy test female childbearing potential : Negative within 7 calendar day randomization study EXCLUSION CRITERIA : The presence follow exclude subject study enrollment : 1 . Prior treatment oxaliplatin bevacizumab . 2 . Any uncontrolled infection . 3 . History myocardial infarction within previous 6 month current clinical evidence congestive heart failure , nonstable coronary artery disease , clinically significant hypertension ( blood pressure &gt; 160/110 mmHg medication ) , symptomatic peripheral vascular disease . 4 . History cancer ( except non melanoma skin cancer carcinoma insitu cervix ) unless complete remission therapy cancer least 5 year . 5 . Central nervous system metastasis . 6 . Peripheral neuropathy cause . 7 . Pregnant lactating woman . 8 . Hypersensitivity one study drug ingredient . 9 . Participation investigational drug study within 4 week precede enrollment . 10 . Lack physical integrity upper gastrointestinal tract malabsorption syndrome . 11 . Medical psychiatric disorder would interfere informed consent , compliance make poor risk participation trial . 12 . Patients know DPD deficiency . 13 . Patients interstitial pneumonia extensive symptomatic fibrosis lung . 14 . Patients calculate creatinine clearance &lt; 30 ml/min use Cockroft Gault formula . 15 . Patients receive organ allograft . 16 . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior study entry . 17 . Chronic , daily treatment aspirin ( &gt; 325 mg/day ) nonsteroidal antiinflammatory medication ( intermittent `` p.r.n . '' use pain permit ) . 18 . Evidence bleed diathesis coagulopathy . 19 . Subjects find proteinuria baseline If patient find &gt; /= 1+ proteinuria baseline screen undergo 24hour urine collection , must adequate collection must demonstrate &lt; 2g protein/24 hr allow participation study . 20 . Patients chronic therapeutic Warfarin therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>